시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 비근육 침윤성 방광암 시장 보고서(2025년)
Non-Muscle Invasive Bladder Cancer Global Market Report 2025
상품코드 : 1717256
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,265,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,056,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,846,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

비근침윤성 방광암 시장 규모는 향후 수년간 강력한 성장세를 보이며 2029년까지 연평균 5.8%의 연평균 복합 성장률(CAGR)로 46억 1,000만 달러에 달할 것으로 예측됩니다. 예측 기간 중 성장의 원동력은 표적 치료의 채택 증가, 맞춤 의료에 대한 관심 증가, 종양학 연구에 대한 투자 확대, 최소 침습적 시술에 대한 수요 증가, 만성 방광 질환의 유병률 증가에 기인할 것으로 보입니다. 예상되는 주요 동향으로는 기술 발전, 정밀의료의 발전, 인공지능의 통합, 원격의료 서비스의 확대, 디지털 헬스 툴의 채택 등이 있습니다.

최소침습수술에 대한 수요가 비근육침윤성 방광암 시장의 성장을 촉진할 것으로 예측됩니다. 최소침습수술은 작은 절개창과 특수기구를 사용하는 수술법으로 기존 개복수술에 비해 조직 손상이 적고, 통증이 적으며, 회복 시간이 짧고, 흉터를 최소화할 수 있는 수술법입니다. 회복 기간 단축, 환자 결과 개선, 고령화 인구 증가 등의 요인으로 인해 저침습 기술이 강조되고 있으며, 환자의 안전성, 만족도, 의료 효율성이 향상되고 있습니다. 비근육침윤성 방광암은 경요도적 절제술이나 방광내 치료와 같은 국소 치료를 통해 대규모 수술적 개입 없이 종양을 치료할 수 있습니다. 예를 들어 2023년 8월 The Aesthetic Society는 미국인들이 미용 성형에 118억 달러 이상을 지출했다고 보고했으며, 이는 전년 대비 2% 증가한 수치입니다. 결과적으로 최소침습적 시술에 대한 수요 증가는 비근육 침습성 방광암 시장을 촉진하고 있습니다.

맞춤의료에 대한 관심은 비근육침윤성 방광암 시장의 성장을 더욱 촉진할 것으로 예측됩니다. 맞춤의료는 보다 효과적인 결과를 얻기 위해 개인의 유전자 프로파일, 생활습관, 환경에 맞는 치료를 하는 것입니다. 이러한 접근법은 유전체 연구의 발전, 진단 툴의 개선, 표적 치료에 대한 수요 증가로 인해 더욱 탄력을 받고 있습니다. 비근침윤성 방광암은 특정 종양의 특징, 유전자 마커, 환자 프로파일에 따라 맞춤형 치료 계획을 세울 수 있다는 점에서 맞춤의료에 부합합니다. 예를 들어 Personalized Medicine Coalition은 2024년 2월 FDA가 2022년 6건, 2023년 16건의 희귀질환에 대한 새로운 개인맞춤형 치료제를 승인했다고 보고한 바 있습니다. 이러한 개인화 접근법에 대한 관심은 시장 성장에 크게 기여하고 있습니다.

목차

제1장 개요

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나바이러스의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 대기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 합병과 인수

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSA
영문 목차

영문목차

Non-muscle invasive bladder cancer (NMIBC) is a type of bladder cancer localized to the inner layers of the bladder wall, without infiltration into the muscle layer. It is generally diagnosed at an early stage and can often be effectively managed through treatments such as transurethral resection, intravesical therapy, or close monitoring.

The main stages of NMIBC include carcinoma in situ (CIS), T1 stage, and Ta stage. Carcinoma in situ refers to abnormal cells confined to the bladder lining without spreading to deeper tissues. Treatment options for NMIBC include immunotherapy, chemotherapy, surgery, intravesical therapy, and others, with tumors categorized as low-grade or high-grade. The end users for NMIBC treatments include hospital pharmacies, retail pharmacies, and online pharmacies.

The non-muscle invasive bladder cancer market research report is one of a series of new reports from The Business Research Company that provides non-muscle invasive bladder cancer market statistics, including non-muscle invasive bladder cancer industry global market size, regional shares, competitors with a non-muscle invasive bladder cancer market share, detailed non-muscle invasive bladder cancer market segments, market trends and opportunities, and any further data you may need to thrive in the non-muscle invasive bladder cancer industry. This non-muscle invasive bladder cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-muscle invasive bladder cancer market size has grown strongly in recent years. It will grow from $3.46 billion in 2024 to $3.67 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth during the historical period can be attributed to an aging population, increased healthcare spending, improved healthcare infrastructure, the expansion of telemedicine, and a rise in smoking rates.

The non-muscle invasive bladder cancer market size is expected to see strong growth in the next few years. It will grow to $4.61 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. Projected growth in the forecast period is expected to be driven by the rising adoption of targeted therapies, an increasing focus on personalized medicine, growing investments in oncology research, heightened demand for minimally invasive procedures, and a rising incidence of chronic bladder conditions. Key trends anticipated include advancements in technology, the development of precision medicine, the integration of artificial intelligence, the expansion of telemedicine services, and the adoption of digital health tools.

The demand for minimally invasive procedures is anticipated to drive the growth of the non-muscle invasive bladder cancer market. These procedures involve surgical techniques utilizing small incisions and specialized instruments, resulting in less tissue damage, reduced pain, shorter recovery times, and minimal scarring compared to traditional open surgery. Factors such as shorter recovery periods, improved patient outcomes, and a growing aging population contribute to the rising emphasis on minimally invasive techniques, enhancing patient safety, satisfaction, and healthcare efficiency. Non-muscle invasive bladder cancer facilitates these procedures through localized treatments such as transurethral resection and intravesical therapy, which target tumors without extensive surgical intervention. For example, in August 2023, The Aesthetic Society reported that Americans spent over $11.8 billion on aesthetic procedures, reflecting a 2% increase from the previous year. Consequently, the increasing demand for minimally invasive procedures is boosting the non-muscle invasive bladder cancer market.

The focus on personalized medicine is expected to further fuel the growth of the non-muscle invasive bladder cancer market. Personalized medicine tailors medical treatments to an individual's genetic profile, lifestyle, and environment to achieve more effective outcomes. This approach is gaining momentum due to advancements in genomic research, improved diagnostic tools, and a rising demand for targeted treatments. Non-muscle invasive bladder cancer aligns with personalized medicine by enabling customized treatment plans based on specific tumor characteristics, genetic markers, and patient profiles. For instance, the Personalized Medicine Coalition reported in February 2024 that the FDA approved 16 novel personalized therapies for rare diseases in 2023, compared to six approvals in 2022. This focus on personalized approaches is significantly contributing to the market's growth.

Key players in the non-muscle invasive bladder cancer market are advancing immunotherapy to enhance treatment options and patient outcomes. Immunotherapy utilizes the body's immune system to detect and combat cancer by boosting or activating immune responses. For instance, in March 2024, ImmunityBio Inc., a biotechnology company, received FDA approval for ANKTIVA (N-803) to treat patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) featuring carcinoma in situ (CIS), with or without papillary tumors. This approval, based on promising clinical trial results, highlights ANKTIVA's effectiveness when combined with Bacillus Calmette-Guerin (BCG), offering a viable option for patients unresponsive to standard BCG therapy. ANKTIVA, an innovative IL-15 agonist immunotherapy, works by stimulating natural killer (NK) cells and CD8+ killer T cells, enhancing the immune system's ability to target and destroy cancer cells.

Major players in the non-muscle invasive bladder cancer market are Johnson & Johnson, Janssen Research & Development LLC, Merck & Co. Inc., AstraZeneca plc, Moderna Inc., Astellas Pharma US Inc., Ferring Pharmaceuticals, EMD Serono Inc., Fidia Farmaceutici SpA, Genentech Inc., Aura Biosciences Inc., UroGen Pharma Ltd., Asieris Pharmaceuticals, Protara Therapeutics Inc., Hamlet Pharma AB, Istari Oncology Inc., Heat Biologics Inc., Telormedix SA, Viventia Bio Inc., Theralase Technologies Inc., Vaxiion Therapeutics Inc., ImmunityBio Inc., Altor BioScience Corporation, SURGE Therapeutics Inc.

North America was the largest region in the non-muscle invasive bladder cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in non-muscle invasive bladder cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the non-muscle invasive bladder cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-muscle invasive bladder cancer market consists of revenues earned by entities by providing services such as diagnostic services, patient support services, and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-muscle invasive bladder cancer market also includes sales of molecular profiling kits and bladder instillation devices. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Muscle Invasive Bladder Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-muscle invasive bladder cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for non-muscle invasive bladder cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-muscle invasive bladder cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Non-Muscle Invasive Bladder Cancer Market Characteristics

3. Non-Muscle Invasive Bladder Cancer Market Trends And Strategies

4. Non-Muscle Invasive Bladder Cancer Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Non-Muscle Invasive Bladder Cancer Growth Analysis And Strategic Analysis Framework

6. Non-Muscle Invasive Bladder Cancer Market Segmentation

7. Non-Muscle Invasive Bladder Cancer Market Regional And Country Analysis

8. Asia-Pacific Non-Muscle Invasive Bladder Cancer Market

9. China Non-Muscle Invasive Bladder Cancer Market

10. India Non-Muscle Invasive Bladder Cancer Market

11. Japan Non-Muscle Invasive Bladder Cancer Market

12. Australia Non-Muscle Invasive Bladder Cancer Market

13. Indonesia Non-Muscle Invasive Bladder Cancer Market

14. South Korea Non-Muscle Invasive Bladder Cancer Market

15. Western Europe Non-Muscle Invasive Bladder Cancer Market

16. UK Non-Muscle Invasive Bladder Cancer Market

17. Germany Non-Muscle Invasive Bladder Cancer Market

18. France Non-Muscle Invasive Bladder Cancer Market

19. Italy Non-Muscle Invasive Bladder Cancer Market

20. Spain Non-Muscle Invasive Bladder Cancer Market

21. Eastern Europe Non-Muscle Invasive Bladder Cancer Market

22. Russia Non-Muscle Invasive Bladder Cancer Market

23. North America Non-Muscle Invasive Bladder Cancer Market

24. USA Non-Muscle Invasive Bladder Cancer Market

25. Canada Non-Muscle Invasive Bladder Cancer Market

26. South America Non-Muscle Invasive Bladder Cancer Market

27. Brazil Non-Muscle Invasive Bladder Cancer Market

28. Middle East Non-Muscle Invasive Bladder Cancer Market

29. Africa Non-Muscle Invasive Bladder Cancer Market

30. Non-Muscle Invasive Bladder Cancer Market Competitive Landscape And Company Profiles

31. Non-Muscle Invasive Bladder Cancer Market Other Major And Innovative Companies

32. Global Non-Muscle Invasive Bladder Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-Muscle Invasive Bladder Cancer Market

34. Recent Developments In The Non-Muscle Invasive Bladder Cancer Market

35. Non-Muscle Invasive Bladder Cancer Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기